A Phase 2/3 interventional study of EffCaMgCit and CaAcS in CKD Stage 5, sponsored by University of Texas Southwestern Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by University of Texas Southwestern Medical Center · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Renal Insufficiency, Chronic by University of Texas Southwestern Medical Center — 5 open to participants now, 6 under way, 1 of them phase 3. Renal Insufficiency, Chronic · University of Texas Southwestern Medical Center.
Among the 11 studies in Renal Insufficiency, Chronic by University of Texas Southwestern Medical Center, this one is the only one that started in 2017, is the only one in phase 2/3, and was the 5th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →5 of the 11 studies in Renal Insufficiency, Chronic by University of Texas Southwestern Medical Center are open now, in 1 country. Recruiting first, the newest first:
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–65 · Healthy volunteers
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 30–69
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 1
First in 2013; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 269 is above the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 60 across the 8 interventional studies, 61 across the 3 observational. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Texas Southwestern Medical Center is the lead sponsor of 1,012 studies on the registry; 200 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.
2 of the studies in Renal Insufficiency, Chronic by University of Texas Southwestern Medical Center that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03565913Phase 3University of Texas Southwestern Medical CenterPotential Therapeutic Role of Effervescent Calcium-Magnesium Citrate in Chronic Kidney Disease Stage V | 2026-12-01 |
| NCT07368946University of Texas Southwestern Medical CenterPhosphate Assessment in Chronic Kidney Disease Patients Study | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Renal Insufficiency, Chronic by University of Texas Southwestern Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Investigators plan to conduct a long-term trial to explore therapeutic implications of effervescent calcium magnesium citrate (EffCaMgCit) in CKD Stage V (end stage renal disease on hemodialysis). The Investigators will test the hypothesis that EffCaMgCit would retard the formation of calciprotein particles (CPP) in CKD Stage V, thereby reducing the degree of coronary artery and peripheral artery calcification and cardiac hypertrophy-fibrosis.
Aim 1. To compare cardiovascular risk of EffCaMgCit versus CaAcS in CKD Stage V Aim 2. To show that EffCaMgCit reduces putative serum FGF23, and increases beneficial alkali load Aim 3. To compare parameters of bone turnover and bone mineral density (BMD) between EffCaMgCit and CaAcS groups
150 adult subjects (> 21 years of age, any cause of CKD) of either gender of any ethnicity with CKD Stage V on hemodialysis will be recruited from Davita-UTSW dialysis centers and randomized into two equal groups in a parallel design, stratified according to gender and age (> or ≤ 50 years). After baseline evaluation, one group (EffCaMgCit Group) will take EffCaMgCit, and the other group (CaAcS Group) will take calcium acetate suspension/solution for two years. Both drugs will be taken 1 sachet each just before or along with breakfast and dinner for the first three months. If tolerated, the dose will be increased to 1 sachet tid just before or along with breakfast, lunch and dinner.
After screening and a baseline evaluation, research personnel will visit patients at the dialysis center every three months for two years. Patients will be evaluated with a medical history, side effect questionnaires, blood pressure measurements, blood tests, echocardiograms, coronary artery calcification analyses, muscle magnesium analyses, and bone mineral density analyses.
It is expected that markers of cardiovascular risk would be improved in patients taking CaMgCit, and would remain stable in those taking CaAcS.
Endpoint Expectations:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients in the EffCaMgCit group will receive 45 meq (900 mg) Ca, 30 meq (365 mg) Mg, and 135 meq total citrate per day from 3 months to 2 years.
Drug: EffCaMgCit
Patients in the CaAcS group will take 45 meq (900 mg) Ca and 45 meq acetate (without Mg or citrate) per day.
Other: CaAcS
Patients in the EffCaMgCit group will receive 45 meq (900 mg) Ca, 30 meq (365 mg) Mg, and 135 meq total citrate per day from 3 months to 2 years.
Also known as: Effervescent calcium magnesium citrate
CaAcS group will take 45 meq (900 mg) Ca and 45 meq acetate (without Mg or citrate), three times daily for 2 years
Also known as: Calcium acetate suspension/solution
Serum T50 for CPP
The maturation time (T50) of calciprotein particles in serum will be measured. T50 CPP (measured by Calcisco using Pasch's method) assays the kinetics of transformation from primary to secondary CPP in vitro. Fresh serum samples will be kept at -80 degrees until shipment to Calcisco AG (Berne, Switzerland) for T50 analysis, which will determine T50 of CPP through research collaboration with CMMCR.
Time frame: 24 months
Intracellular muscle magnesium
Intracellular Mg will be measured in calf muscle, by using 31P magnetic resonance spectroscopy, based on the formula: \[Mg\] - kd(10.796-D)/(D-8.251), in which kd is the dissociation constant for MgATP complex (=50 µM) and D is the chemical shift difference between alpha- and beta-ATP 31P signals observed in 31P MR spectrum.
Time frame: 24 months
Control of hyperphosphatemia and serum FGF23
The control of hyperphosphatemia will be evaluated from changes in serum P concentration, serum FGF23 and Klotho.
Time frame: 24 months
Parathyroid function and bone turnover
Parathyroid function will be evaluated from serum PTH, vitamin D status from serum calcitriol, bone resorption from serum CTX, and bone formation from serum BSAP. Change in bone mass will be evaluated by BMD (proximal femur, L2-L4 spine and distal third of radius).
Time frame: 24 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2017 (actual). Primary completion is estimated for Dec 2026, 118 months after the start.
Of 11 phase 2/3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 56. This study's planned 118 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Effervescent calcium magnesium citrate
Renal Insufficiency, Chronic →
University of Texas Southwestern Medical Center →